Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Labetalol Hydrochloride Tablets USP in the strengths of 100 mg, 200 mg, and 300 mg. Labetalol Hydrochloride Tablets are used to treat high blood pressure (hypertension). The drug will be manufactured at the group's formulations manufacturing facility at the Pharrna SEZ, Ahmedabad.
The group now has more than 150 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
